Key result
Vitamin D supplementation shows no benefit over placebo for overall mortality in advanced heart failure.
Why the study?
Vitamin D supplementation is widely used, but its effects on mortality and cardiovascular outcomes in patients with heart failure are unclear, prompting evaluation of potential latency effects after trial closure.
Does vitamin D supplementation reduce overall mortality in patients with advanced heart failure?
Population
Patients with advanced heart failure
Comparison
4000 IU vitamin D daily vs placebo
Design
3-year post-intervention follow-up of a randomized placebo-controlled trial
Follow-up
3 years after closure (6 year period overall)
Authors
Loading...
No mortality benefit from vitamin D in advanced HF; confirms lack of efficacy and supports avoiding routine supplementation.
RCT
Placebo-controlled
Randomized
Does vitamin D supplementation reduce overall mortality in patients with advanced heart failure?
Hazard Ratio: 1.07 (95% CI 0.68–1.7)
Absolute Event Rate: 38.8% vs 36.5%
Vitamin D supplementation at 4000 IU daily does not improve overall mortality in advanced heart failure and may increase the risk of hospitalization and need for mechanical circulatory support during active treatment.
Zittermann et al. (2020) conducted an RCT in Advanced heart failure. Vitamin D vs. Placebo was evaluated on overall mortality (HR 1.07, 95% CI 0.68-1.70). Vitamin D supplementation (4000 IU daily) in advanced heart failure showed no beneficial latency effect on overall mortality during a 3-year post-intervention follow-up (HR 1.07; 95% CI 0.68-1.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: